Quel est le prix pour Biocept, Inc. (BIOC)

Le prix pour Biocept, Inc. (BIOC) est $0.053

Quelle est la capitalisation boursière pour Biocept, Inc. (BIOC)

La capitalisation boursière pour Biocept, Inc. (BIOC) est $23.67K

Biocept, Inc. (BIOC) Prix et Capitalisation Boursière

Biocept, Inc. is a company specializing in molecular diagnostics for cancer, primarily focused on developing and commercializing advanced diagnostic assays based on proprietary technology. These tests analyze circulating tumor cells (CTCs) and cell-free tumor DNA and RNA (ctDNA/ctRNA), primarily using standard blood samples. These assays furnish crucial insights to healthcare professionals, enabling them to identify specific genetic changes (oncogenic alterations) that qualify certain cancer patients for targeted therapies. This information is vital throughout the patient journey: at initial diagnosis, during disease progression, and for ongoing monitoring to detect the emergence of treatment resistance. Their diagnostic portfolio extends to various solid tumor types, including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. Beyond blood-based diagnostics, Biocept offers specialized testing services for cerebrospinal fluid (CSF), analyzing tumor cells, ctDNA, and ctRNA. These services cater to a broad spectrum of medical specialists, such as medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, and pathologists. Furthermore, the company supports pharmaceutical and biopharmaceutical companies, along with clinical research organizations (CROs), through its clinical trial and research services. Additionally, Biocept provides RT-PCR testing for COVID-19. In strategic partnerships, Biocept collaborates with CLEARED4 on a system designed to track and manage COVID-19 testing requirements and results for clients. Another collaboration involves Protean BioDiagnostics, Inc., focusing on research into the efficacy of Biocept's proprietary Target Selector molecular assay for determining EGFR status in non-small cell lung cancer (NSCLC) patients. Established in 1997, Biocept, Inc. operates from its headquarters in San Diego, California.

Prix pour BIOC	L’actif B	La capitalisation boursière de B	Résultats
$12,055,176 $23.67K	NVDA	$5.383T	+22,745,615,270.83%
$9,905,480 $23.67K	AAPL	$4.423T	+18,689,585,037.78%
$9,316,485 $23.67K	GOOG	$4.160T	+17,578,272,882.74%
$8,203,424 $23.67K	MSFT	$3.663T	+15,478,157,611.28%
$6,474,446 $23.67K	AMZN	$2.891T	+12,215,936,550.32%

Prix pour BIOC

L’actif B

La capitalisation boursière de B

Résultats

$12,055,176 $23.67K